Perspective

FDA-approved dry eye therapy from Sun available Q4

The FDA has approved Cequa for the treatment of dry eye disease, Sun Pharmaceutical Industries announced in a press release.

Cequa (cyclosporine ophthalmic solution 0.09%), the highest FDA-approved concentration of cyclosporine A and the first to incorporate nanomicellar technology, is indicated to increase tear production, the release said.

“Dry eye disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated,” Abhay Gandhi, Sun Pharma North America CEO, said in the release. “The U.S. FDA approval of Cequa represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun’s Ophthalmics business. Cequa, with its novel nanomicellar formulation for a proven dry eye medication, delivers a lipophilic molecule in a clear solution form.”

A company spokesperson told Primary Care Optometry News that Cequa will be available in the fourth quarter of 2018.

The FDA has approved Cequa for the treatment of dry eye disease, Sun Pharmaceutical Industries announced in a press release.

Cequa (cyclosporine ophthalmic solution 0.09%), the highest FDA-approved concentration of cyclosporine A and the first to incorporate nanomicellar technology, is indicated to increase tear production, the release said.

“Dry eye disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated,” Abhay Gandhi, Sun Pharma North America CEO, said in the release. “The U.S. FDA approval of Cequa represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun’s Ophthalmics business. Cequa, with its novel nanomicellar formulation for a proven dry eye medication, delivers a lipophilic molecule in a clear solution form.”

A company spokesperson told Primary Care Optometry News that Cequa will be available in the fourth quarter of 2018.

    Perspective
    Marc R. Bloomenstein

    Marc R. Bloomenstein

    The FDA approval of Cequa provides eye care clinicians with another tool to help alleviate dry eye. The challenge of treating dry eye signs and symptoms is complicated by the multifactorial nature of this chronic disease. Therefore, finding the right combination of medication, lid management and environmental constraints all contribute to ensuring the patient will be able to control the disease. The opportunity to have more options for our patients is a win-win for everyone that is dealing with dry eye.

    • Marc R. Bloomenstein, OD, FAAO
    • Schwartz Laser Eye Center, Scottsdale, Ariz.
      Primary Care Optometry News Editorial Board member

    Disclosures: Bloomenstein reports he is on the speaker panel for Alcon, Allergan, Bausch + Lomb, Johnson & Johnson and TearLab. He is a consultant for Akorn, Allergan, Bausch + Lomb, Bio-Tissue, Johnson & Johnson, OcuSoft, Reichert and TearLab.